Avecris develops the SPRING DNA technology platform to create a new class of programmable genetic medicines. This platform enables sustained, cell-type specific gene expression for delivering therapeutic proteins with long-lasting effects. The technology overcomes prior limitations in gene delivery, allowing for redosable, immune-quiet, non-integrating gene cargo of any size.
Funding
$10K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene delivery methods often struggle with achieving precise cell-type specificity, sustained therapeutic protein production, and avoiding immune system activation, which limits the efficacy and safety of genetic medicines. Traditional methods using viral vectors also pose risks of insertional mutagenesis.
Solution
Avecris is developing the SPRING DNA platform, a non-viral gene delivery system designed for precise and sustained cell-type-specific gene expression. The SPRING DNA technology utilizes a unique, rationally designed DNA vector that is non-integrating and elicits a minimal immune response, enabling long-lasting therapeutic protein production. The platform's modular design allows for the conjugation of targeting moieties like antibodies and aptamers to achieve tissue-specific delivery. SPRING DNA's small size and lack of free ends contribute to its stability and resistance to exonucleases, further enhancing its therapeutic potential. An innovative on/off switch mechanism allows for precise control of gene expression, minimizing off-target effects.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing gene therapies and genetic vaccines for chronic diseases.
Features
- Non-integrating DNA vector design to eliminate the risk of insertional mutagenesis
- Modular architecture allowing conjugation of targeting ligands for cell-type specificity
- Sustained protein expression for durable therapeutic effect
- Minimalistic size and structure resistant to exonucleases and innate immune activation
- Innovative on/off switch for precise control of gene expression
- Scalable and reliable manufacturing process for cost-effective production
- More stable than mRNA and next-wave RNA